Cargando…

Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters

PURPOSE: The phase III trial of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel for first-line treatment of HER2-positive metastatic breast cancer included a substudy to determine whether pertuzumab affected the corrected QT (QTc) interval or other electroca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garg, Amit, Li, Jing, Clark, Emma, Knott, Adam, Carrothers, Timothy J., Marier, Jean-François, Cortés, Javier, Brewster, Michael, Visich, Jennifer, Lum, Bert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825499/ https://www.ncbi.nlm.nih.gov/pubmed/23999693 http://dx.doi.org/10.1007/s00280-013-2279-6

Ejemplares similares

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
por: Miles, David, et al.
Publicado: (2013)

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study
por: Xu, Binghe, et al.
Publicado: (2022)

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
por: Kuemmel, Sherko, et al.
Publicado: (2021)

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2020)

Prolonged QTc in HIV-Infected Patients: A Need for Routine ECG Screening
por: Myerson, Merle, et al.
Publicado: (2019)

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
por: Mortimer, Joanne, et al.
Publicado: (2014)

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
por: Howell, Sacha J., et al.
Publicado: (2020)

Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)
por: Thill, Marc, et al.
Publicado: (2022)

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
por: Quartino, Angelica L., et al.
Publicado: (2017)

The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
por: Takahashi, Masato, et al.
Publicado: (2020)

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
por: Xu, Binghe, et al.
Publicado: (2020)

Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
por: Darpo, Borje, et al.
Publicado: (2014)

Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients
por: Ansermot, Nicolas, et al.
Publicado: (2019)

Diagnostic accuracy of a single‐lead portable ECG device for measuring QTc prolongation
por: Bekker, Charlotte L., et al.
Publicado: (2019)

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
por: Arpino, Grazia, et al.
Publicado: (2023)

Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
por: Darpo, Borje, et al.
Publicado: (2014)

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane
por: Pohlmann, Paula R., et al.
Publicado: (2022)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno, I, et al.
Publicado: (2015)

Absence of QTc Prolongation with Domperidone: A Randomized, Double-Blind, Placebo- and Positive-Controlled Thorough QT/QTc Study in Healthy Volunteers
por: Biewenga, Jeike, et al.
Publicado: (2015)

Paroxetine‐induced QTc prolongation
por: Otsuka, Yuji
Publicado: (2017)

“Prevalence of Brugada pattern ECG and prolonged QTc in ECG of patients with Schizophrenia – A Cross sectional Study at the in-patient department of a tertiary care centre”
por: Divya, C R1, et al.
Publicado: (2022)

Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects
por: Täubel, Jörg, et al.
Publicado: (2016)

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
por: Kirschbrown, Whitney P., et al.
Publicado: (2019)

Problems with Bazett QTc correction in paediatric screening of prolonged QTc interval
por: Andršová, Irena, et al.
Publicado: (2020)

Significance of prolonged QTc in acute exacerbations of COPD requiring hospitalization
por: Van Oekelen, Oliver, et al.
Publicado: (2018)

Associations of Prolonged QTc in Sickle Cell Disease
por: Indik, Julia H., et al.
Publicado: (2016)

QTc interval prolongation in HIV-infected patients: a case–control study by 24-hour Holter ECG recording
por: Fiorentini, Alessandra, et al.
Publicado: (2012)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
por: Kirschbrown, Whitney P., et al.
Publicado: (2019)

Ketamine-induced QTc interval prolongation
por: Singh, Tejinder S. Swaran, et al.
Publicado: (2017)

Hydroxychloroquine: QTc prolongation: case report.
Publicado: (2020)

Evaluation of the potential for QTc prolongation with avelumab
por: Vugmeyster, Yulia, et al.
Publicado: (2019)

Ticagrelor-Induced Prolongation of the QTc Interval
por: Ray, Avik, et al.
Publicado: (2019)

An overview of QTc Prolongation with antipsychotics and antidepressants
por: Bhandari, Samrat Singh, et al.
Publicado: (2022)

The Effect of COVID-19 on QTc Prolongation
por: Alsallamin, Isaac, et al.
Publicado: (2022)

The corrected QT (QTc) prolongation in hyperthyroidism and the association of thyroid hormone with the QTc interval
por: Lee, Ye Seung, et al.
Publicado: (2015)

Influence of different second generation antipsychotics on the QTc interval: A pragmatic study
por: Olsen, Roy E, et al.
Publicado: (2016)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
por: Mendell, Jeanne, et al.
Publicado: (2015)

Sources of QTc variability: Implications for effective ECG monitoring in clinical practice
por: Hnatkova, Katerina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_63o2pvho9dvo5ls28hcgrer46k